UROLOGIC CLINICS OF NORTH AMERICA Urol Clin N Am 30 (2003) 891-915 Cumulative Index Volume 30 February UROLOGIC MANIFESTATIONS OF NEUROLOGIC DISEASE. pages 1-180 May LOCALIZED PROSTATE CANCER, pages 181-422 August CONTEMPORARY MANAGEMENT OF RENAL CELL CARCINOMA. pages 423-668 November FOLLOW-UP STRATEGIES AND MANAGEMENT OF RECURRENCE IN UROLOGIC ONCOLOGY, pages 669-915 Note: Page numbers of article titles are in boldface type. A fertility, 101-102 Aarskog syndrome, in children, 160 infections, 103-105 Kaposi's sarcoma, 102-103 Abscesses, prostatic, in AIDS, 104-105 lymphomas, 103 Acid-base abnormalities, after urinary tract nephrolithiasis, 99-100 reconstruction, for recurrent bladder prostate cancer, 103 cancer, 784 prostatic abscesses, 104-105 prostatitis, 104-105 Acupuncture, for prostate cancer, 374 renal cell carcinoma, 103 Acute renal failure, partial nephrectomy and, 536 squamous cell carcinoma, 103 vascular surgery and, 21-22 testicular atrophy, 101 testicular neoplasms, 103 Adenocarcinoma, prostatic. See Prostatic voiding dysfunction, 100-101 adenocarcinoma. Alcohol, as risk factor, for prostate cancer, 214 Adhesion molecules, as markers, for renal cell carcinoma, 457-458 Allogeneic stem cell transplant, for metastatic renal cell carcinoma, graft-versus-tumor Adjuvant immunotherapy, for metastatic renal response in, 618-620 cell carcinoma, 595 limitations of, 618 Adoptive immunotherapy, for metastatic renal rationale for, 613-615 cell carcinoma, 593-595 results of, 615, 617 toxicity of, 618 Adrenal androgen inhibitors, for prostate cancer, for renal cell carcinoma, 611-622 after treatment failure, 409 rationale for, 612-613 Adrenal glands, involvement of, by renal cell Alport’s syndrome, in children, 160 carcinoma, 469-470, 486 Aminoglutethimide, for prostate cancer, after Adrenal insufficiency, tuberculosis and, 111 treatment failure, 409 Afferent pathways, in micturition, 27 Amputation, for squamous penile carcinoma, AgNORS, as markers, for renal cell carcinoma, 857-858 491-492 Amygdalin, for prostate cancer, 372 AIDS, urologic complications of, 99-107 Anabolic steroids, and male infertility, 84 carcinoma in situ, 103 erectile dysfunction, 101 Androgel, for hypogonadism, 74-75 0094-0143/03/S - see front matter © 2003 Elsevier Inc. All rights reserved. doi: 10.1016 S0094-0143(03)00078-8 892 Cumulative Index | Urol Clin N Am 30 (2003) 891-915 Androgen ablation therapy. for prostate cancer. Atherosclerosis. and renovascular See Hormonal therapy. hypertension, 13 Androgen abnormalities, and erectile Atrophic carcinoma, of prostate, diagnosis of, 196 dysfunction. See Erectile dysfunction. Atypical small acinar proliferation, clinical and male infertility, 86-87, 147 significance of, 184-185, 672 Androgen blockade, for prostate cancer, after Autologous blood donation, before radical treatment failure, 409-410 prostatectomy, 365 Androgen deprivation therapy, for prostate Autologous bone marrow transplant, for cancer, 345, 353-354 neuroblastoma, &86 after treatment failure, 406 for prostatic adenocarcinoma, 197-198 Autosomal dominant polycystic kidney disease, in children, 161 Androgen receptor genes, in prostate cancer, 211 Autosomal recessive polycystic kidney disease, in Angiography, digital subtraction, of renovascular children, 160-161 hypertension, 15 magnetic resonance, of renovascular hypertension, 15-16 B Bacille Calmette-Guerin, for bladder cancer, Angiomas, retinal, von Hippel- Lindau disease 768-769 and, 131 failure of, 771-772 Angiomyolipomas, imaging of, 506-507 Balanitis xerotica obliterans, and squamous penile tuberous sclerosis complex and, 837 carcinoma, 853 Angioplasty, percutaneous transluminal renal, Bardet-Biedl syndrome, in children, 161 for ischemic nephropathy, 18-19 for renovascular hypertension, 17 Bax, as marker, for renal cell carcinoma, 456-457 Anthracyclines, for Wilms’ tumor, complications bel-2, as marker. for renal cell carcinoma, of, 871 456-457, 492 Antiandrogen therapy, for prostate cancer, after Benign prostatic hyperplasia. prostate-specific treatment failure, 408, 759-760 antigen in, 223, 267-268 physical burden of, 307 Bexarotene, for renal cell carcinoma, 606 Antibody imaging. of prostate cancer, 288 BHD gene, in renal cell carcinoma, 449 after treatment failure, 393. 394 Bicalutamide, for prostate cancer, after treatment Antigens, in renal cell carcinoma, 460-462 monoclonal antibodies and, 626 failure, 408, 759-760 Bile acid absorption, after urinary tract Antioxidants, in prevention, of prostate cancer, 230, 231 reconstruction, for recurrent bladder cancer. 784 Antiphospholipid antibody syndrome, and thromboembolic disease, 57 Biopsy, of lymph nodes, for prostatic adenocarcinoma, 192 Antitumor immune response, in renal cell of prostate cancer, 253-262,280-281 carcinoma, 428-430 after treatment failure, 392-393, 753 Apomorphine, for erectile dysfunction, 7 artificial neural networks and, 254-255 complications of, 260-261 Arteriography, of renovascular hypertension, 15 Gleason grade and, 259, 260 pharmacologic, of erectile dysfunction, 21 pathology and, 255-256 Artificial neural networks, and biopsy. of prostate prostate-specific antigen parameters and, cancer, 254-255 253-254 prostate volume and, 256-257 Ascending pathways. in micturition, 28 technique for, 257-258 Asphyxiating thoracic dysplasia, in children, 163 when to stop, 258-260 Cumulative Index | Urol Clin N Am 30 (2003) 891-915 893 of prostatic fossa, after radical prostatectomy, Bones, involvement of, by recurrent seminoma, 712 808 by renal cell carcinoma, 845, 850 Birt-Hogg-Dube syndrome, and renal cell carcinoma, 137, 446-447, 449-450 Bosniak classification, of cystic renal masses, genetics of, 835-836 507-511 Bladder cancer, 765-776 Botanicals, for prostate cancer, 370, 372 extravesical recurrence of, 769-771 Bowel dysfunction, prostate cancer treatment positive urine cytology and no and, 310-311 demonstrable disease in, 770-771 prostatic urethral disease, 770 Bowenoid papulosis, and squamous penile refractory, intravesical therapy for, 771-772 carcinoma, 854-855 radical cystectomy for, 772 Brachytherapy, interstitial. See Interstitial upper tract disease, 767-770 brachytherapy. intravesical therapy for, 768-769 nonurologic medications and, 127 Brain, involvement of, by renal cell carcinoma, recurrent, 777-789 845, 849 distant, 778-779 Brain-imaging studies, in neurologic diseases, 32 local, 777-778 upper tract, 779-781 Brain stem, function of, in micturition, 28 management of, 780-781 Branchio-oto-renal syndrome, in children, 162 natural history of, 779 risk of, 779-780 Bromocriptine, for hyperprolactinemia, 76 surveillance of, 780 urethral, 770, 781-784 Cc management of, 782-784 Capecitabine, for renal cell carcinoma, 602. 604 natural history of, 781-782 Captopril renogram, in renovascular risk of, 782 hypertension, 15 surveillance of, 783 urinary tract reconstruction for, Carbergoline. for hyperprolactinemia, 76 complications of, 784-785 Carcinoembryonic antigen, as marker, for renal restaging transurethral resection of, 767-768 cell carcinoma, 492 transurethral evaluation and resection of, 766-767 Carcinoma in situ, and squamous penile tumor types in, 765-766 carcinoma, 855 in AIDS, 103 Bladder dysfunction, tuberculosis and, 112 Cardiac complications, of management, of Bladder emptying, disorders of, nonurologic Wilms’ tumor, 870-871 medications and, 122 Cardiovascular assessment, before radical Bladder exstrophy, and male infertility, 148 prostatectomy, 364 Bladder filling. disorders of, nonurologic CD44, as marker, for renal cell carcinoma, 460 medications and, 122-123 Central nervous system, recurrent Bladder tumor antigen test, for recurrent nonseminomatous tumors of, 827 transitional cell carcinoma, 796 recurrent seminoma of, 808 Blood glucose control, for diabetes mellitus, 3-4 Cerebral centers, in micturition, 28-29 Body composition, in prostate cancer, 213 Cerebrohepatorenal syndrome, in children, 166 Bone marrow transplant, for neuroblastoma, 886 Cerebrovascular disease. See Neurologic diseases. Bone scans, of prostate cancer, after radical CHARGE syndrome, in children, 162 prostatectomy, 710-711 after treatment failure, 754 Chemoprevention, of prostate cancer, 227-237 894 Cumulative Index Urol Clin N Am 30 (2003) 891-915 Chemoprevention (continued ) Clear cell sarcoma, renal, prognosis for. 874 antioxidants in, 230, 231 recurrent, 877 COX-2 inhibitors in, 233-234 Colic. tuberculosis and, 111-112 hormones in, 232 Prostate Cancer Prevention Trial in. Collagenous micronodules, in prostatic 232-233 adenocarcinoma, 190 risk factors and, 227-230 Collecting duct carcinoma, genetics of, age, 228 426, 443 ethnicity, 228 nuclear morphometry of. 474-475 family history, 228-229 prognosis for, 488 genetics, 229 insulin-like growth factor-1, 230 Colloid carcinoma, of prostate, histology of. prostate-specific antigen level, 228 195-196 serum factors, 229-230 Colorectal cancer, genitourinary involvement by. SELECT in, 232 63-65 selenium in, 230-231 vitamin E in, 231 Comedocarcinoma, Gleason grade in, 188 Chemotherapy. for bladder cancer, 769 Complementary and alternative medicine, for for leukemia, urologic complications of, 5 prostate cancer, 333, 369-376,690 for neuroblastoma, 886 acupuncture in, 37 surgery after, 885 botanicals in, 370, 372 for nonseminomatous tumors, 821-822 detoxification in, 371—372 for prostate cancer, after radical diets in, 371 prostatectomy, 716-717 for symptom control, 373 after treatment failure, 411 high-dose vitamins in, 371 for recurrent bladder cancer. 781 laetrile in, 372 for recurrent nonseminomatous tumors. metabolic therapies in, 371-372 825-826 PC-SPES in, 370 for recurrent seminomas, 805-808 prevalence of, 369-370 for renal cell carcinoma, 601-609 vitamin E in, 374 chemoimmunotherapy in, 603-605 Complex adherin, as marker, for renal cell combination, 602-603 carcinoma, 457-458 retinoids in, 605-606 single-agent. 602 Computed tomography, of angiomyolipomas. for seminomas, complications of, 810-811 506-507, 837 recurrence after, 808-809 of hereditary papillary renal cell for squamous penile carcinoma, 860-861 carcinoma, 834 for tuberculosis. 118 of nonseminomatous tumors. 820 for Wilms’ tumor, 876 of prostate cancer, 285-286 complications of, 871 after radical prostatectomy. 711 after treatment failure, 394-395 Chromophobe renal cell carcinoma. genetics of, r recurrent transitional cell carcinoma, 796 426, 442-443 ‘renal cell carcinoma, 502-503 prognosis for, 487-488 technique for, 499-500 Chromosomal abnormalities, in male infertility, Condyloma acuminatum, and squamous penile 142-145 carcinoma, 854 Chromosome 3 translocations, and renal cell Congenital adrenal hyperplasia. and male carcinoma, 448 infertility, 83-84 Ciliary dyskinesia, and male infertility, 148 Congenital bilateral absence of vas deferens, and Clear cell carcinoma, genetics of, 425-426. male infertility, 145, 154-155 441-442. 448. 838 COX-2 inhibitors, in prevention, of prostate prognosis for, 487 cancer, 233-234 Cumulative Index | Urol Clin V Am 30 (2003) 891-915 895 Crohn's disease. See Gastrointestinal disorders, Cyproterone acetate, for prostate cancer, after inflammatory bowel disease. treatment failure, 408 Cryotherapy, for prostate cancer, 725-736 Cystadenomas, epididymal. von Hippel-Lindau after treatment failure, 756 disease and, 154 anatomic issues in, 728 Cystectomy, bladder cancer after. See Bladder and impotence, 730 cancer, recurrent. and incontinence, 730-731 and pelvic and rectal pain, 731 Cystic fibrosis, and male infertility. 145-146, and penile numbness, 731 154-155 and rectourethral fistula, 731—-732 and urolithiasis, 93-94 and tissue sloughing, 731 Cystic masses, renal, classification of, 507-511 and urethral stricture, 732 imaging of, 507-511 controversies in, 733-735 pseudoenhancement of, 511 equipment for, 727 factors affecting, 726-727 Cystitis, hemorrhagic, chemotherapy and, 56 failure of. treatment options after, 733 tuberculosis and. 112 follow-up of, 730 Cystometry. in neurologic diseases, 31 future trends in, 733-735 historical aspects of, 725-726 Cystopathy. diabetic. See Diabetes mellitus. lymph node dissection with, 728 Cysts, pancreatic, von Hippel Lindau disease mechanism of ablation by, 726 and, 132-133 neoadjuvant hormonal therapy with, 728 renal, tuberous sclerosis complex and, 837 patient selection for, 727-728 postoperative care for, 730 Cytadren, for prostate cancer, after treatment failure, 409 preoperative preparation for, 728-729 prostate-specific antigen after, 730, 732-733 Cytokine-based therapy. for metastatic renal cell results of, 732-733 carcinoma, 589-600,61 2 technique for, 729-730 adjuvant immunotherapy in, 5 tumor histology and, 728 adoptive immunotherapy in, for recurrent prostate cancer, after interstitial combination therapy in, 592 brachytherapy. 746 interferons in, 591-595, 612 for renal cell carcinoma, 565-569, 571, interleukins in, 590-595, 612 838-839 lymphokine-activated killer cells in, 594 clinical observations in, 567-568 rationale for, 589-590 contraindications to, 567 tumor-infiltrating lymphocytes in, equipment for, 566 594-595 follow-up of. 569, 571 Cytology, of recurrent transitional cell carcinoma, indications for, 566-567 796 pathophysiology of. 565 566 results of, 568-569 Cytoreductive surgery, for metastatic renal cell technique for, 567 carcinoma, 548, 581-588 Phase II randomized trials on. 87 Cryptophthalmos syndrome, in children, 162 rationale for, 581-583 Cryptorchidism, and risk of seminomas, 812 retrospective single-institution series on, 583-585 Crystalloids. in prostatic adenocarcinoma. 189-190 Cushing’s syndrome, and male infertility, 87 D Cutaneous horn, and squamous penile Dendritic cell-based tumor vaccines, for renal cell carcinoma, 853 carcinoma. See Tumor vaccines. Cyclins, as markers, for renal cell carcinoma, Depression, prostate cancer and, 298 Cyclophosphamide, and bladder cancer, 127 Detoxification, for prostate cancer, 371-372 896 Cumulative Index Urol Clin V Am 30 (2003) 891-915 Detrusor areflexia. cerebrovascular disease E and, 37 Eagle-Barrett syndrome, and male infertility. Parkinson's disease and parkinsonism and, 42 in children, 164 Detrusor contractility, impaired. cerebrovascular Efferent pathways. in micturition, 27—28 disease and, 37 Ehlers-Danlos syndrome. in children. 162 Detrusor hyperreflexia, cerebrovascular disease Ejaculatory dysfunction, and male infertility, 148 and, 36 diabetes mellitus and, 84 Parkinson's disease and parkinsonism and, in AIDS, 101 41-42 nonurologic medications and. 123, 126 Dexamethasone, for prostate cancer, after vascular surgery and, 22-23 treatment failure, 409 Electrolyte imbalance. after urinary tract Diabetes mellitus, 1-12 reconstruction, for recurrent bladder cancer. and cystopathy, 1-4 784 diagnosis of, 1-3 Electromyography. in neurologic diseases, 31 management of, 3-4 in Parkinson's disease and parkinsonism. pathogenesis of, 3 39-40 and ejaculatory dysfunction, 84 and erectile dysfunction, 4-7, 85 Endocrinopathies, genetic. and male infertility. diagnosis of, 5 146-147 management of, 6—7 Endometrioid carcinoma, of prostate, histology pathogenesis of, 5-6 of. 194-195 and male infertility, 84-85 and spermatogenesis, 84-85 Endoscopic surgery. for recurrent bladder cancer. 780-781 Dietary factors, in prostate cancer, 212-213. for recurrent transitional cell carcinoma. 670-671 794-795 Diethylstilbestrol, for prostate cancer. after in surveillance. of recurrent transitional cell treatment failure, 407 carcinoma, 798-799 Digital rectal examination, of prostate cancer. Endothelin-1. for prostate cancer. after radical after radical prostatectomy. 709 prostatectomy, 717 after treatment failure, 393 Energy factors. in prostate cancer, 213 of recurrent prostate cancer, 699 Enteric hyperoxaluria, management of. 67-68 Digital subtraction angiography. of renovascular hypertension, 15 Environmental factors, in prostate cancer. 912-214 Diverticulitis, urologic complications of, 65-66 Epididymal cystadenomas, von Hippel-Lindau DNA alterations, in epithelial renal tumors, disease and. 154 438 441 Epididymitis. nonurologic medications and, 127 DNA ploidy. in renal cell carcinoma, 472-473, 491 Erectile dysfunction, androgen abnormalities and. Doppler ultrasonography, of prostate cancer, OFnRe II= SOe 71-79 chemically induced, 75 DOX, for Wilms’ tumor, complications of, 871 hypogonadism, 71~75 testosterone preparations for, 73 75 Doxorubicin, for renal cell carcinoma, 603 diabetes mellitus and. See Diabetes mellitus. Ductal carcinoma, of prostate. histology of, diagnosis of, 20-21 194-195 growth hormone deficiency and. 76 Duplex ultrasonography, of erectile dysfunction. in AIDS, 101 20-21 interstitial brachytherapy and, 357~—359 of renovascular hypertension, 15 lipid disorders and. 76 Cumulative Index Urol Clin V Am 30 (2003) 891-915 nonurologic medications and, 123 urinary, partial nephrectomy and, 536 prolactinomas and, 75-76 Floxuridine, for renal cell carcinoma, 602 radical pelvic surgery and, 66-67 radical prostatectomy and, 367 Fluoropyrimidines, for renal cell carcinoma, 602, thyroid disease and. 76 604 vascular surgery and, 22-23 5-Fluorouracil. for renal cell carcinoma, 603, 604 Estrogen therapy, for prostate cancer. after Flutamide, for prostate cancer, after treatment treatment failure, 406-407 failure, 408 Exisulind, for prostate cancer, after radical Foamy gland carcinoma, of prostate, diagnosis of, prostatectomy. 717 196 External beam radiation therapy. See also Folinic acid. for renal cell carcinoma, 603 Radiation oncology. for prostate cancer, and sexual dysfunction, Follicle-stimulating hormone, disorders of, and 309 male infertility. 147 and urinary dysfunction, 310 Fraser syndrome, in children, 162 failure of, secondary treatment of. See Prostate cancer, secondary Fuhrman grading system. for renal cell treatment of. carcinoma, 472. 486 in favorable-risk patient, 339-342 in high-risk patient, 344-345 G in intermediate-risk patient, 342-344 G250 antigens, in renal cell carcinoma, 462 interstitial brachytherapy after, 738-740 G250 monoclonal antibody, as marker, for renal for squamous penile carcinoma, cell carcinoma, 457, 492-493 856-857 as therapy. for renal cell carcinoma, 626-629 Extraprostatic extension, of prostatic Gastrointestinal complications, of radiation adenocarcinoma, 191-192 therapy. for prostate cancer, 324 Gastrointestinal disorders, 61-70 F colorectal cancer, 63-65 Factor V Leiden mutation, and thromboembolic diverticulitis. 65-66 disease. 57 inflammatory bowel disease, 61-63 and urolithiasis, 92-93 Fat, dietary. and prostate cancer. 671 fistulas in, 62-63 FDG-PET imaging, of recurrent seminomas, postoperative complications in, 63 808-809 ureteral obstruction in, 61-62 nephrolithiasis, 67-68 Female stress urinary incontinence, Parkinson's pelvic surgery for. and erectile dysfunction, disease and parkinsonism and, 42 66-67 Fertility, after treatment, for seminomas, 811 and vesicourethral dysfunction, 66 in AIDS, 101-102 and voiding dysfunction, 66 Fetal face syndrome, in children. 164-165 Gemcitabine, for renal cell carcinoma, 603 Finasteride, for prostate cancer, after treatment Gene therapy. for diabetes mellitus, 4 failure, 408-409 Genetic disorders, and male infertility. See Male in prevention, of prostate cancer, 232 infertility. Fistulas, inflammatory bowel disease and. in children, 159-167 62-63 Aarskog syndrome, 160 rectal, interstitial brachytherapy and, 357 Alport’s syndrome, 160 rectourethral, after cryotherapy, for prostate autosomal dominant polycystic kidney cancer, 731-732 disease, 161 retroperitoneal, nonurologic medications and. autosomal recessive polycystic kidney 127 disease, 160-161 89S Cumulative Index | Urol Clin N Am 30 (2003) 891-915 Genetic disorders (continued ) Goserelin, for prostate cancer, after treatment Bardet-Biedi syndrome, 161 failure, 407 branchio-oto-renal syndrome, 162 Gout, and urolithiasis, 93 CHARGE syndrome, 162 Ehlers-Danlos syndrome, 162 Graft-versus-tumor response, in allogeneic stem evaluation of, 159-160 cell transplantation, for renal cell carcinoma, Fraser syndrome, 162 618-620 Goldenhar syndrome, 162 Graves’ disease, and male infertility, 85-86 hypertelorism-hypospadias syndrome, 162 intersex disorders, 162-163 Gray-scale ultrasonography, of prostate cancer, Jeune syndrome, 163 282-285 Lesch-Nyhan syndrome, 163 Growth factor deficiency, and erectile Meckel-Gruber syndrome, 163 dysfunction, 76 Menkes disease, 163 MURCS syndrome, 163 Growth factors, in prostate cancer, 211-212 nail-patella syndrome, 163-164 Noonan syndrome, 164 iH oculocerebrorenal syndrome of Lowe, 164 Head and neck, involvement of, by renal cell Prader-Willi syndrome, 164 carcinoma, 849-850 prune-belly syndrome, 164 Hemangioblastomas, central nervous system, Robinow syndrome, 164-165 von Hippel Lindau disease and, 131-132 sickle cell anemia, 165 Smith-Lemli-Opitz syndrome, 165 Hematologic diseases, 49-60 Turner syndrome, 165 leukemia, 55-56 VACTERL syndrome, 165 leukemic infiltration and tumor Wilms’ tumor, 165-166 compression in, 55-56 Zellweger syndrome, 166 management of, urologic complications of, 56 Genetic testing, for renal cell carcinoma, 449-450 priapism in, 55 Genistein, and lower risk, of prostate urolithiasis in, 55 cancer, 671 sickle cell anemia, 49-55, 151-152 and male infertility, 148 Genitourinary complications, of radiation hematuria in, 50 therapy, 56 in children, 165 for prostate cancer, 324 inheritance patterns in, 49-50 Germ cell tumors. See Seminomas. nephropathies in, 50 Gleason grade, in prostate cancer, 187-189, 259, nephrotic syndrome in, 51-52 260, 264 papillary necrosis in, 50-51 after radical prostatectomy, 704, 706 priapism in, 53-55, 151, 165 after treatment failure, 391 proteinuria in, 51 and radical prostatectomy, 364, 365 renal failure in, 52 renal medullary carcinoma in, 53 Glomerular disease, after treatment, for Wilms’ renal tubular abnormalities in, 52 tumor, 871 testicular infarction in, 55 Glomeruloid pattern, in prostate cancer, 196 urinary tract infections in, 52-53 vesicular infections in, 55 Glucocorticoids, for prostate cancer, after thromboembolic disease, 57-59 treatment failure, 409 antiphospholipid antibody syndrome in, 57 Goldenhar syndrome, in children, 162 Henoch-Schénlein purpura in, 58—59 hereditary hypercoagulable syndromes in, 57 Gonadal complications, of management, of in neonates, 58 Wilms’ tumor, 872 in pregnancy, 57 Gonadotropin-releasing hormone, disorders of, membranous nephropathy and nephrotic and male infertility, 146-147 syndrome in, 58 Cumulative Index | Urol Clin N Am 30 (2003) 891-915 neoplasms in, 57-58 Hyperoxaluria, and urolithiasis, 91-92 management of, 67-68 Hematospermia, prostate biopsy and, 261 Hyperparathyroidism, and urolithiasis, 90-91 Hematuria, prostate biopsy and, 260 sickle cell anemia and, 50 Hyperprolactinemia, and erectile dysfunction, tuberculosis and, 111-112, 115-116 75-76 and male infertility, 86 Hemorrhagic cystitis, chemotherapy and, 56 Hypertelorism-hypospadias syndrome, in Henoch-Schénlein syndrome, and children, 162 thromboembolic disease, 58-59 Hyperthyroidism, and male infertility, 85-86 Hepatic complications, of management, of Wilms’ tumor, 871-872 Hyperuricemia, and urolithiasis, 93 High-intensity focused ultrasonography, Hypogonadism, and erectile dysfunction, 71~75 therapeutic, for renal cell carcinoma, 573-575 testosterone preparations for, 73-75 and male infertility, 82-84 HIV infection, condyloma acuminatum with, 854 genitourinary tuberculosis with, 111 Hypomethylation, in renal cell carcinoma, 440 Hormonal therapy, for prostate cancer, 692-699 Hyposthenuria, sickle cell anemia and, 52 after radical prostatectomy, 714-716 Hypothalamic-pituitary-testicular axis, in male after treatment failure. See Prostate cancer, infertility, 81 secondary treatment of. and osteoporosis, 696-697 Hypothyroidism, and male infertility, 86 and sarcopenia, 697-698 and weight gain and obesity, 698 I as adjuvant therapy, 693-694 Immune response, following laparoscopic radical as neoadjuvant therapy, 694 nephrectomy, for renal cell carcinoma, as primary therapy, 693 548. 549 cryotherapy with, 728 in renal cell carcinoma, 428-430 for metastatic disease, 695-696 for relapse, 694 ImmunoCyt test, for recurrent transitional cell for stage T1-2 disease, 694-695 carcinoma, 796 for stage T3-4 disease, 695 Immunogenic tumor antigens, in renal cell recurrence after, 698-699 carcinoma, 460 Hormone ablation therapy, for prostate cancer, Immunotherapy. See a/so Allogeneic stem cell physical burden of, 307 transplantation. Hormones, in prevention, of prostate cancer, 232 adjuvant, for metastatic renal cell carcinoma, in prostate cancer, 211-212 595 Hoxsey regimen, for prostate cancer, 372 adoptive, for metastatic renal cell carcinoma, 593-595 HPC] gene, in familial prostate cancer, 669-670 for recurrent bladder cancer, 781 HPC2 gene, in familial prostate cancer, 670 for renal cell carcinoma, molecular biology and, 431-432 HPCX gene, in familial prostate cancer, 670 rationale for, 611-612 Human kallikrein-2, in prostate cancer, 268-269 Impotence, after cryotherapy, for prostate versus prostate-specific antigen, 268-269 cancer, 730 Hydrocortisone, for prostate cancer, after Incontinence, after cryotherapy, for prostate treatment failure, 409 cancer, 730-731 Hypercoagulable syndromes, and Indinavir, and nephrolithiasis, 99-100 thromboembolic disease, 57 and urolithiasis, 95, 127 Hypermethylation, in renal cell carcinoma, 431 Infections, in tuberculosis. See Tuberculosis. 900 Cumulative Index | Urol Clin N Am 30 (2003) 891-915 Infections (continued) results of, 355, 738-740 prostate biopsy and, 260 software in, 352-353 urologic, in AIDS, 103-105 technique for, 354 for squamous penile carcinoma, 857 Infertility, male. See Male infertility. Intracavernous injection and self-stimulation test. Inflammatory bowel disease. See Gastrointestinal for erectile dysfunction, 20 disorders. Intracavernous injections, of vasoactive agents, Inguinal lymph nodes, in squamous penile for erectile dysfunction, 6—7 carcinoma, 858, 862-863 Intracavitary photon radiation therapy, for renal Insulin-like growth factor-1, in prostate cancer, cell carcinoma, 575, 577 211-212, 230, 269 Intratubular germ cell neoplasia. and risk of Intensity-modulated radiation therapy, for seminomas, 811-812 prostate cancer, 341-343 Intravesical therapy, for bladder cancer, 768-769, Interferons, for metastatic renal cell carcinoma, 771-772 590-595. 603-606, 612 Irritative voiding symptoms, interstitial Interleukins, for metastatic renal cell carcinoma, brachytherapy and, 357 590-595. 612 in prostate cancer, 271-272 Ischemic nephropathy. See Vascular disease. Intersex disorders. in children, 162-163 Isotretinoin, for renal cell carcinoma, 605-606 Interstitial brachytherapy. See also Radiation oncology. J for prostate cancer, 351-362, 737-750 Jeune syndrome, in children, 163 after treatment failure, 756-757 and bowel dysfunction, 311 k and quality of life, 359 Kallmann syndrome, and male infertility, 146 and sexual dysfunction, 309 and urinary dysfunction, 310 Kaposi's sarcoma, in AIDS, 102-103 dosimetry in, 354-355 Kartagener syndrome, and male infertility, 148 failure of, secondary treatment of. See Prostate cancer, secondary Karyometric markers, for renal cell carcinoma. treatment of. 460 follow-up of, 740-742 Kennedy's disease, and male infertility, 147, 156 biopsy in, 742 physical examination in, 741-742 Ketoconazole, for prostate cancer, after treatment post-implant dosimetry. 740-741 failure, 409 prostate-specific antigen in, 742 Ki-67, as marker, for renal cell carcinoma, 457. hardware in, 351-352 492 hormonal therapy with, 353-354 in favorable-risk patient, 339-342 Klinefelter syndrome, and male infertility, 82. isotopes in, 738 144-145 morbidity in, 356-359 patient selection for, 353 L prostate-specific antigen after, 742 Laetrile, for prostate cancer, 372 recurrent disease after, 742-743 Laparoscopic nephroureterectomy,. for recurrent salvage cryotherapy for. 746 transitional cell carcinoma, 793-794 salvage radiation therapy for, 745-746 salvage radical. prostatectomy for, Laparoscopic partial nephrectomy, for renal cell 744-745 carcinoma, 551, 553-563, 565 staging and risk stratification of, complications of, 559-561 743-744 contraindications to, 551, 553